IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation.
about
Interleukin-33 and Mast Cells Bridge Innate and Adaptive Immunity: From the Allergologist's PerspectiveInnate lymphocyte cells in asthma phenotypesIL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin.Allergic asthma: influence of genetic and environmental factors.Interleukin-33 primes mast cells for activation by IgG immune complexesThe novel cytokine interleukin-33 activates acinar cell proinflammatory pathways and induces acute pancreatic inflammation in mice.Amplification of cytokine production through synergistic activation of NFAT and AP-1 following stimulation of mast cells with antigen and IL-33Identification of an IFN-γ/mast cell axis in a mouse model of chronic asthma.IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk.Skin barrier disruption: a requirement for allergen sensitization?IL-33 family members and asthma - bridging innate and adaptive immune responses.IL-33 promotes MHC class II expression in murine mast cells.Regulation of mast cell responses in health and disease.Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity.Generation of potent mouse monoclonal antibodies to self-proteins using T-cell epitope "tags".IL-33 induces a hyporesponsive phenotype in human and mouse mast cells.Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33.Innate lymphoid cells in asthma: Will they take your breath away?Role of adenosine A(2B) receptors in inflammation.Role of the IL-33-ST2 axis in sepsis.Signaling pathways critical for allergic airway inflammation.The enigmatic processing and secretion of interleukin-33.The many paths to asthma: phenotype shaped by innate and adaptive immunity.Targeting the IL-1 family members in skin inflammation.Pathogenesis of severe asthma.Mast Cells Respond to Cell Injury through the Recognition of IL-33.Novel identified receptors on mast cells.Interleukin-33: a mediator of inflammation targeting hematopoietic stem and progenitor cells and their progenies.Emerging role of interleukin-33 in autoimmune diseases.Immunobiology of critical pediatric asthma.New dog and new tricks: evolving roles for IL-33 in type 2 immunity.Influence of IL-6, IL-33, and TNF-α on human mast cell activation: Lessons from single cell analysis by flow cytometry.Interleukin-33: increasing role in dermatological conditions.Transcriptional Heterogeneity of Mast Cells and Basophils upon Activation.SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors.Lactic Acid Suppresses IL-33-Mediated Mast Cell Inflammatory Responses via Hypoxia-Inducible Factor-1α-Dependent miR-155 Suppression.Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration.Regulatory T cells and regulation of allergic airway disease.TGF-β1 Suppresses IL-33-Induced Mast Cell Function.Didox (3,4-dihydroxybenzohydroxamic acid) suppresses IL-33-induced cytokine production in primary mouse mast cells.
P2860
Q26775911-A310CC72-C93A-4696-8CC0-4974A7344591Q27010139-8E75C03F-406D-4353-ADC9-8C9776DE2157Q33732911-1EA72F59-C77B-49E9-B71B-16F2F827DE5BQ34204432-376D95E8-075B-4C74-9E10-5D72F8E4009EQ34448122-16193D5B-D7BD-44C3-A67D-66AD9B55912CQ34590317-206EC224-ED2C-441E-A7D2-21CB87530E00Q34895161-B4F459E6-925B-4485-A91B-64A6BD6BCF63Q35142807-3A572452-882A-41C8-BDEF-786190BF86E6Q35565295-D408B3DD-32A3-4D57-A339-642F3722D390Q35757285-B68DCA90-A6AC-4923-A926-7EEB0BA78774Q36050546-EF1DB018-1526-4329-91EC-855EB07EE90DQ36082314-064B3816-740F-4A11-B26F-DE8CE6414889Q36092456-756E3629-E755-433F-8E46-D140F244E7F0Q36157993-F17E01C2-4D64-4A19-8EF6-CBF4B743A5FBQ36211494-BBCCE3DF-0F46-4F55-8EE2-362039EDFE39Q36514301-FBEB65C6-9ABA-4DFB-9051-21DC6B7D1AB6Q36744984-997541BC-AF18-4DB2-95D3-45F1961A11B3Q36973089-637D527C-3588-48C9-9F0F-2BB0D27D8DE7Q37108355-C27119AF-B5A7-4A5B-A949-CA56CA8BDD2BQ37620811-649E9A20-CB4C-451B-9E80-FFC10A63E02BQ37649335-050D9A3D-F218-497D-803D-AC2772D7127DQ37715704-D967F2C1-BE44-407B-81F7-0FCB94B1C7A4Q37766451-C545E7C0-D05D-47EF-B1F0-0A5EE2306DA7Q37820911-026EBE6B-AA49-43B9-8BCB-BBAC93BB86CEQ38003659-5061E3DD-A561-49D0-AA33-FAC38BD1FDB3Q38008374-83A45790-B753-490E-9175-B97727DA026DQ38033164-9A3F588A-7AE9-474B-895D-FCE6C546E6CFQ38105069-EF4EB9DE-CE77-4BC7-A2F7-47E0DD14D0D2Q38151715-40830886-439A-4AB5-9FE1-7E8656460E8CQ38181015-C42B9338-4F3E-4735-B733-83EBB64AE10DQ38388349-34293900-C4AD-473B-95CF-097CCB6B0410Q38627886-DF24AC4E-2F13-4DD5-996D-C5F18DB0DC7FQ38770982-D54A1353-2FE2-4C2A-945D-7A3E92B72060Q38801289-94630447-D04F-4491-8EFC-1A1C17F377F7Q39276466-CDB8D7C2-6E67-4EBB-B603-650AAB07FD0EQ39455563-A927A744-28FB-4BDF-9678-F01B2D86F5DBQ41097407-F2E484F8-D13D-433F-8EDE-57939FE48186Q43087975-A71BEF79-0B88-4F88-A0FD-DF4830F4728AQ45061841-18244320-4B93-47A5-A95E-1816C9BE7A03Q45064301-78B75285-75A2-4589-9DA5-FE6BF71D3BA2
P2860
IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
IL-33 synergizes with IgE-depe ...... cell and basophil activation.
@en
IL-33 synergizes with IgE-depe ...... cell and basophil activation.
@nl
type
label
IL-33 synergizes with IgE-depe ...... cell and basophil activation.
@en
IL-33 synergizes with IgE-depe ...... cell and basophil activation.
@nl
prefLabel
IL-33 synergizes with IgE-depe ...... cell and basophil activation.
@en
IL-33 synergizes with IgE-depe ...... cell and basophil activation.
@nl
P2093
P2860
P1476
IL-33 synergizes with IgE-depe ...... cell and basophil activation.
@en
P2093
Alexander Margulis
Divya Chaudhary
Marion Kasaian
Matthew R Silver
Nancy Wood
Samuel J Goldman
P2860
P2888
P304
P356
10.1007/S00011-009-0088-5
P577
2009-09-18T00:00:00Z